Schedule 13D ownership disclosure
LYRA THERAPEUTICS INC
Common Stock, $0.001 par value · CUSIP: 55234L105
Event date: 2025-08-12
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Perceptive Advisors LLCReported CIK 0001224962
Shares: 255,750 · Class: 15.55%
- Joseph EdelmanReported CIK 0001164426
Shares: 255,750 · Class: 15.55%
- Perceptive Life Sciences Master Fund, Ltd.Reported CIK 0001249675
Shares: 229,982 · Class: 13.99%
- Perceptive LS (A), LLCReported CIK 0001797811
Shares: 25,768 · Class: 1.57%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000950170-25-109077
- Form type
- SCHEDULE 13D/A
- Filer
- Lyra Therapeutics, Inc.
- CIK
- CIK 1327273
- Filed
- Aug 14, 2025
- Reporting period
- Aug 12, 2025
- Description
- Schedule 13D beneficial ownership